RMD

Health Technology
$196.04 +0.89%
Back to Screener
Live Volume
1,536,646
Market Cap
28.44 B
P/E Ratio
18.90
52W Peak Proximity
%67

ANALYSIS CENTER

AI Rating & Analysis: RMD stock analysis with hallucination-free AI screener tools — real-time price, volume, P/E ratio, 52-week proximity and sector performance data for Health Technology. AI-powered stock analysis and research platform.
GOD-TIER PROMPT ACTIVE
Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level
10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.
1Executive Summary
2Fair Value
3Fundamental Analysis
4Technical Analysis
5Scenario Analysis
6Competitor Comparison
7Dividend Return
8Risk Analysis
9Catalyst Calendar
10Action Plan
HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.
İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.
Open Advanced Chart
TradingView Charts
• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — RMD

ResMed Inc. — Company Profile & Analysis

ResMed Inc., founded in 1989 and headquartered in San Diego, California, is a global leader in developing, manufacturing, distributing, and marketing medical devices and cloud-based software applications designed to diagnose, treat, and manage respiratory disorders. The company's core mission is to improve the quality of life for millions of people suffering from conditions such as sleep apnea, COPD (Chronic Obstructive Pulmonary Disease), and other chronic respiratory ailments. ResMed is dedicated to transforming patient care by leveraging technology to help individuals lead healthier, more active lives. Since its inception, the company has established itself as a pioneer in the field of respiratory health, offering innovative solutions that address critical unmet needs.

The company operates through two primary segments: Sleep and Breathing Health, and Residential Care Software. The Sleep and Breathing Health segment encompasses a comprehensive range of devices for the diagnosis and treatment of sleep apnea and other sleep-disordered breathing conditions. This includes portable diagnostic devices like ApneaLink Air and NightOwl, which measure key physiological parameters for accurate diagnosis, as well as solutions for sleep labs such as EasyCare Tx. Complementing these hardware offerings, ResMed provides advanced digital health solutions, including AirView, a cloud-based platform enabling remote monitoring and adjustment of patient device settings, and myAir, a personalized therapy management application that enhances patient engagement and adherence through tailored support, education, and troubleshooting tools. The Residential Care Software segment offers integrated solutions and services for organizations in home medical equipment, pharmacy, orthotics and prosthetics, home infusion, home health, and hospice sectors, featuring platforms like Brightree, HEALTHCAREfirst, and MatrixCare EHR, which are designed to optimize clinical, financial, and administrative processes.

ResMed boasts a significant global presence, reaching a vast network of patients and healthcare providers worldwide. Its primary target demographic includes individuals diagnosed with sleep apnea, COPD, and other forms of respiratory failure. The company serves a diverse clientele, including sleep clinics, hospitals, home care organizations, and individual patients. Through its commitment to technological innovation and a patient-centric approach, ResMed has solidified its position as a market leader in respiratory care. Its extensive global distribution network and strategic partnerships ensure that its life-changing products and services are accessible to patients across various geographical regions, ultimately aiming to improve patient outcomes and enhance the efficiency of healthcare systems.

The future outlook for ResMed remains exceptionally strong, driven by favorable demographic trends such as an aging global population, the increasing prevalence of chronic diseases, and a growing demand for home-based healthcare solutions. The company is strategically investing in digital health technologies and AI-powered platforms to further personalize and optimize patient care pathways. ResMed also plans to expand its product portfolio by exploring novel treatment modalities and emerging technologies within the respiratory health domain. Furthermore, strategic acquisitions and collaborations are expected to play a crucial role in enhancing ResMed's market share and diversifying its revenue streams. The company's overarching strategy is to reinforce its leadership in respiratory care by seamlessly integrating cutting-edge technology with essential healthcare services.

Economic Moat ResMed's sustainable competitive advantage is derived from its deep expertise in respiratory care, a robust portfolio of patented technologies, and a comprehensive suite of integrated hardware and software solutions. The company's advanced digital health platforms, such as AirView and myAir, coupled with its data analytics capabilities, create significant network effects by enhancing patient monitoring and therapy adherence. This, combined with its strong relationships with healthcare providers across various settings, positions ResMed as an indispensable partner in managing chronic respiratory conditions.
CEO Mr. Michael J. Farrell BE, MBA, SM
Employees 10,600
Headquarters United States
Market Competitors
Smart Tags
#ResMed #HealthTech #SleepApnea #COPD #MedicalDevices #DigitalHealth #NASDAQ:RMD #RespiratoryCare

Market Insights & Investor Q&A — RMD

Frequently Asked Questions

Is there a ready-made prompt to quickly check RMD's cash flow coverage ratio?
Yes, DocuRefinery offers an instant template for the cash flow coverage ratio. It uses verified data, works with no signup, and delivers the analysis within seconds.
How can I obtain free cash flow to debt for RMD using an AI-powered tool?
DocuRefinery provides a ready-made AI prompt for free cash flow to debt. The prompt pulls real data with no registration and returns a hallucination-free result instantly.
What are the benefits of using AI prompts for institutional-grade RMD analysis?
AI prompts reduce manual errors, scan large datasets in seconds, and use verified data. With DocuRefinery’s ready-made solutions, investors get instant, reliable insights without the need for complex spreadsheet models.

Deep Analysis

AI-Powered Ready Solutions for RMD Investment Analysis

Modern AI methods automate risk assessment and trend detection for stocks like RMD, giving investors a clear edge. DocuRefinery lets you launch these processes with a single prompt, pulling verified data, scanning balance sheets, and calculating key ratios in an instant.

Traditional analysis often involves manual data gathering and lengthy modeling. In contrast, AI-driven ready prompts deliver real data with no signup and provide instant results, allowing a deep dive into the stock within minutes.

Prompt engineering enables you to tailor analysis strategies to specific needs. With DocuRefinery’s templates for metrics such as free cash flow to debt or cash flow coverage ratio, you can achieve accurate, hallucination-free outcomes quickly, saving both time and resources.